Angiotensin converting enzyme (ACE) inhibitors inhibit both the formation of angiotensin II and the catabolism of bradykinin (BK).sion of angiotensin I into angiotensin II (ATII). ACE inhibitors block not only ATII formation but also bradykinin (BK) degradation. Some pharmacological effects of ACE inhibitors are mediated by endogenous preservation of BK. BK is a potent vasodilator peptide, which possesses cardioprotective action via BK B2 receptor. The binding of BK to B2 receptor activates second messengers that induce a broad spectrum of biological effects, such as vasodilation, inflammation and cell proliferation (5, 6). In cardiovascular systems, BK mediates important effects, including increased vascular permeability, enhanced myocardial glucose uptake,